HER3-DXd for advanced solid tumors after prior treatment
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced or metastatic solid tumor that cannot be surgically removed.
- You have had at least one prior therapy for your cancer that stopped working (the number depends on your cancer type).
- You are able to provide a tumor sample (biopsy) from before starting this trial.
- You are in good enough health to be up and about (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
This trial tests a new combination treatment for people with advanced solid tumors that have HER2 changes. The goal is to see if it can shrink tumors or slow growth.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This trial tests a new drug called Dato-DXd for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to help stop the cancer from growing.
This study tests a new drug called HER3-DXd (alone or combined with other medicines) for people with advanced breast cancer that has already been treated with T-DXd (Enhertu) and then got worse. The goal is to see if the new drug can shrink tumors safely.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.